ArticleAsian Pacific journal of cancer prevention : APJCP2025
Biomarker Panels Associated with Diagnosis and Overall Survival in Hepatocellular Carcinoma Revealed from Protein-Protein and mRNA-miRNA Interaction Networks.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated bioinformatics and molecular docking identify novel key genes, pathways, and potential candidate drugs in papillary thyroid carcinoma.Journal, genetic engineering & biotechnology · 2026Article
- Integrated serum proteomics and metabolomics reveal an INR-associated multi-omics signature in hepatocellular carcinoma.Clinical proteomics · 2026Article
- A bioinformatics analysis to identify shared molecular pathways and hub genes between NAFLD and Gestational Diabetes Mellitus.Gastroenterology and hepatology from bed to bench · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC), the most common form of liver cancer, has a significant mortality rate, largely due to late diagnosis. Recent advances in medical research have demonstrated the potential of biomarkers for early detection. Moreover, the discovery and use of prognostic biomarkers offer a ray of hope in the fight against liver cancer.
methodsThree gene transcript collections (GSE57957, GSE76427, and GSE84402) were retrieved from the GEO database, and significantly expressed genes were identified through a comprehensive screening process. Subsequently, key potential biomarkers were identified using various methods, including functional pathway enrichment, protein-protein interaction network analysis, mRNA-miR interaction study, and ROC curve and survival analysis.
resultsAfter analyzing the expression of hub proteins and miRs, 12 proteins were found to have AUC values greater than 0.9 and log-rank KM-plot p values less than 0.05. Therefore, these proteins can be considered as potential diagnostic and prognostic biomarkers. Among these proteins, the top 5 were CDC6, PTTG1, CDCA5, RACGAP1, and RAD51AP1. The microRNAs with the highest diagnostic significance (AUC≥0.8) were hsa-mir-101-3p, hsa-mir-195-5p, hsa-mir-130a-3p, hsa-mir-26b-5p, hsa-mir-29c-3p, hsa-mir-26a-5p, and hsa-mir-34a-5p. Notably, hsa-mir-34a-5p, hsa-mir-195-5p, and hsa-mir-130a-3p also showed prognostic potential as predictors of overall survival in HCC patients.
conclusionHarnessing the potential of these biomarkers will enable healthcare professionals to make informed decisions, leading to improved care and more favorable outcomes in the fight against HCC. However, the next step is to thoroughly validate these potential markers in large cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.